C-Myc is one of the most common targets of genetic alterations in human cancers. Although overexpression of c-Myc in the B cell compartment predisposes to lymphomas, secondary mutations are required for disease manifestation. In this article, we show that genetic deficiencies causing arrested B cell development and accumulation of B cell progenitors lead to accelerated lymphomagenesis in E c-myc transgenic mice. This result suggests that B cell progenitors are more prone than their mature counterparts to developing secondary oncogenic lesions that complement c-Myc in promoting transformation. To investigate the nature of these oncogenic lesions, we examined E c-myc mice deficient in mismatch repair function. We report that Msh2 ؊/؊ E c-myc and Msh2 G674A/G674A E c-myc mice rapidly succumb to pro-B cell stage lymphomas, indicating that Msh2-dependent mismatch repair function actively suppresses c-Myc-associated oncogenesis during early B cell development.
B
cell development is a highly regulated process that begins with commitment of pluripotent hematopoietic stem cells to the B cell lineage, followed by a series of differentiation events that ultimately lead to the generation of effector cells, namely antibody-secreting plasma cells. Malignant transformation of B cells can occur at any stage during B lymphopoiesis, and human malignancies representing all stages of B cell development have been described (1) .
The protooncogene c-Myc is commonly found to be deregulated in B cell neoplasms and cancers of other cell types (2) . Although the exact function of c-Myc has not been established, current evidence suggests that c-Myc is a transcription factor or chromatin remodeler that regulates the expression of many genes controlling diverse cellular functions, such as cell proliferation, differentiation, and apoptosis (3, 4) . Overexpression of c-Myc in the B cell lineage in E c-myc transgenic (Tg) mice leads to the development of lymphomas (5, 6) . However, constitutive c-Myc overexpression is not sufficient to transform cells, because lymphomas that develop in E c-myc mice are usually monoclonal and disease incidence is variable, which indicates that secondary oncogenic lesions are required for transformation. Indeed, mutations in loci such as pim-1, bmi-1, and bla-1 (7) and in components of the ARF-Mdm2-p53 pathway (8) are found to be associated with c-Myc-induced lymphomagenesis.
Some secondary mutations that cooperate with c-Myc to transform cells must occur during the early stages of B cell development, because a significant number of E c-myc mice develop pro/pre-B cell lymphomas (5, 6) . Moreover, it has been suggested that E c-myc Tg B cells that have undergone transformation may continue to differentiate (6, 9) . This notion suggests that some mature B cell lymphomas that overexpress c-Myc may have received secondary oncogenic hits during earlier stages of development. Although the precise origin of these secondary oncogenic lesions are not clear, it is possible that processes involved in B cell development or the environment in which B cells develop is inherently mutagenic. If this were the case, it is likely that normal DNA repair mechanisms actively suppress tumor-conducive secondary mutations. One such potential pathway is the mismatch repair pathway (MMR), which is involved in repairing mutations induced during DNA replication and other processes (10) . Importantly, MMR-deficient mice and patients have increased mutation frequencies and are predisposed to cancer development (11) (12) (13) . In this study, we show that B cell progenitors display enhanced susceptibility to neoplastic transformation and that Msh2, a key element of the MMR process, is responsible for suppressing mutations that complement c-Mycassociated oncogenesis during early B cell development.
Results

Precursor B Cells Display Enhanced Susceptibility to c-Myc-Induced
Lymphomagenesis. We previously showed that RAG1 Ϫ/Ϫ E c-myc mice exhibit accelerated lymphomagenesis (14) . A potential explanation for this observation is that T cell immunity, which is absent in RAG1
Ϫ/Ϫ mice, may normally suppress c-Myc-induced B cell lymphomas. To investigate this possibility, we bred E c-myc mice to TCR␣ Ϫ/Ϫ mice, which lack mature ␣␤-lineage T cells, including NKT cells. As depicted in Fig. 1A , longitudinal analysis showed no statistical difference in overall survival between TCR␣ ϩ/Ϫ E c-myc and TCR␣ Ϫ/Ϫ E c-myc mice, indicating that ␣␤T cells and NKT cells do not actively suppress lymphomagenesis in E c-myc mice. As earlier work has demonstrated protective antitumor activity mediated by ␥␦T cells (15), we repeated the above analysis with TCR␦ Ϫ/Ϫ mice, which lack mature ␥␦T cells. As shown in Fig.  1B , survival analysis revealed that the absence of ␥␦T cells had no significant impact on lymphomagenesis in E c-myc mice. In addition, f low cytometric analysis showed that the absence of ␣␤-lineage or ␥␦-lineage T cells did not significantly change the phenotype of emerging lymphomas in these mice (Fig. S1) . Together, these data show that immunosurveillance mediated by mature T lymphocytes does not contribute to the suppression of lymphoma development in E c-myc mice.
Because precursor B cells accumulate in RAG1 Ϫ/Ϫ mice (16), a second explanation that could account for accelerated lymphoma development in RAG1 Ϫ/Ϫ E c-myc mice is that B cell progenitors, compared with their mature counterparts, are inherently more prone to c-Myc-induced transformation. To test This article is a PNAS Direct Submission. 1 To whom correspondence should be addressed. E-mail: alberto.martin@utoronto.ca.
This article contains supporting information online at www.pnas.org/cgi/content/full/ 0905965106/DCSupplemental. this notion, we examined c-Myc-induced lymphoma development in MT Ϫ/Ϫ mice, which possess normal T cell development but exhibit arrested B cell development at the pre-B cell stage (17) . As shown in Fig. 1C , MT Ϫ/Ϫ E c-myc mice display accelerated lymphoma development compared with heterozygous control littermates (log rank test, P ϭ 0.0002). Furthermore, the kinetics of lymphoma development in these mice are similar to that observed in RAG1 Ϫ/Ϫ E c-myc mice (14) because of the lack of statistically significant difference between both curves (log rank test, P ϭ 0.1715). These data suggest that B cell progenitors are particularly susceptible to c-Myc-induced transformation.
Inactivation of the Myc-p53 Apoptotic Pathway Is Reduced in Precur-
sor B Cell Tumors from E c-myc Mice. Previous reports showed that the majority of lymphomas that develop in E c-myc mice sustain mutations that disrupt the c-Myc-induced p53-mediated apoptotic pathway (8) . It has been shown that p53 activation is functional throughout B cell development, including precursor B cells (18) and mature B cells (19) . Thus, the enhanced susceptibility of early B cell precursors to transformation might be caused by increased mutagenesis of genes involved in the c-Myc-p53 pathway, leading to defective p53-mediated apoptosis. Disruption of this pathway can be assessed by Western blot for the sustained expression of Arf, Mdm2, or p53 (8) . However, none of six evaluated MT Ϫ/Ϫ E c-myc tumors analyzed by Western blot showed an accumulation of Arf, Mdm2, or p53 ( Fig. 2A) .
A potential explanation for the reduced accumulation of c-Myc-p53 pathway defects observed in MT Ϫ/Ϫ E c-myc mice is that precursor B cells, regardless of their genotype, preferentially acquire lesions in a different pathway. To test this notion, we carried out Western blot analysis of pro/pre B cell (B220 ϩ sIg Ϫ ) and mature B cell lymphomas (B220 ϩ sIg ϩ ) derived from wild-type E c-myc mice. A representative blot is shown in Fig. 2B . We found that 90% (10/11) of B220 ϩ sIg ϩ mature B cell lymphomas from E c-myc mice overexpressed Mdm2, Arf, or p53, either alone or in combination, whereas only 27% (3/11) of B220 ϩ sIg Ϫ pro/pre-B cell lymphomas overexpressed Mdm2 (t test, P ϭ 0.008). Importantly, none of the evaluated pro/pre-B cell tumors overexpressed Arf or p53. Collectively, these data show that the accelerated rate of transformation observed for B cell precursors is not caused by compounded inactivation of the c-Myc-p53 apoptotic pathway. Furthermore, these data suggest that a pathway distinct from the c-Myc-p53 apoptotic pathway is targeted during c-Mycinduced transformation of B cell progenitors.
Msh2-Deficient E c-myc Mice Rapidly Succumb to Lymphomas. As discussed above, secondary oncogenic lesions are required to transform cells in concert with c-Myc overexpression. One explanation for the rapid onset of lymphomas in MT Ϫ/Ϫ E c-myc and RAG1
Ϫ/Ϫ E c-myc mice is that there is a disproportionately high level of mutagenesis during early B cell ontogeny compared with later stages. Although it is still unknown how these secondary defects arise, it is possible that DNA repair mechanisms may actively suppress tumorpromoting secondary alterations. One potential pathway that might function to suppress lymphoma development in E c-myc mice is the MMR pathway, considering its role in repairing mutations. If the accelerated lymphomagenesis observed in MT Ϫ/Ϫ E c-myc or RAG1 Ϫ/Ϫ E c-myc mice is the result of increased mutational burden in precursor B cells relative to mature B cells, it follows that Msh2 Ϫ/Ϫ E c-myc mice may develop higher proportions of pro/pre-B cell lymphomas than mature B cell lymphomas, and they may do so at a higher rate.
As shown in Fig. 3 , Msh2 Ϫ/Ϫ E c-myc mice succumbed far more rapidly to B cell lymphoma than their Msh2-sufficient controls (log rank test, P Ͻ 0.0001). Because Msh2 has been shown to promote apoptosis, and secondary oncogenic lesions usually lead to defective apoptosis in E c-myc tumors (8), we investigated the contribution of Msh2-induced apoptotic function with regard to tumor suppression in vivo (20) . For this analysis, we used a knockin mutant mouse strain harboring an Msh2 G674A missense mutation within the conserved ATPase domain of Msh2 (21) . This mutation effectively disrupts the DNA repair function of Msh2, while retaining its DNA damage-induced apoptotic function (21) . As shown in Fig. 3 , Msh2
G674A/G674A ⌭ c-myc mice displayed accelerated lymphomagenesis relative to control ⌭ c-myc mice (log rank test, P Ͻ 0.0001), with kinetics similar to Msh2 Ϫ/Ϫ ⌭ c-myc mice (log rank test, P ϭ 0.3262). Notably, the presence or absence of Msh2 did not affect the level of apoptosis in bone marrow-derived precursor B cells ex vivo (Fig. S2) , implying that the effects of Msh2 deficiency are likely caused by the predisposition of B cells to accumulation of genetic lesions, rather than global defects in MMR-dependent apoptosis.
Previous studies showed that deficiency in Msh2 leads to chromosomal aneuploidy (22) . Hence, we investigated whether the accelerated lymphomagenesis observed in Msh2 Ϫ/Ϫ E c-myc mice may be caused by gross chromosomal aberrations (i.e., aneuploidy/chromosomal translocations). A combination of spectral karyotyping and Giemsa banding was carried out on 41 metaphase spreads prepared from short-term cultures of Msh2 ϩ/Ϫ E c-myc lymphoma (derived from two unique tumors) and 62 metaphase spreads prepared from short-term cultures of Msh2 Ϫ/Ϫ E c-myc lymphoma (derived from three unique tumors). We found no significant differences in chromosomal translocations or aneuploidy (Table S1) To determine whether Msh2 deficiency impacts the spectrum of lymphomas that arise in E c-myc mice, we used f low cytometry to categorize the developmental stages of lymphomas, as described (14) (Fig. S3) . As documented (12) , f low cytometric analysis revealed that Msh2-deficient mice developed lymphomas of predominantly CD3 ϩ T cell origin, whereas all E c-myc mice, irrespective of their Msh2 status, developed B220
ϩ B cell lymphomas (see below). As depicted in Fig. 4A , all lymphomas from Msh2 Ϫ/Ϫ E c-myc and Msh2
G674A/G674A E c-myc mice were found to possess a CD3
Ϫ pro-B cell phenotype, distinct from their Msh2-sufficient controls, which developed lymphomas at several different stages of B cell development. The enhanced frequency of progenitor B cell lymphomas observed was not caused by an increased progenitor B cell population in Msh2-deficient mice, because the B lineage compartments between Msh2
Ϫ/Ϫ and Msh2 ϩ/Ϫ preneoplastic mice were similar in the absolute number of cells or percentages (Fig. S4) , irrespective of the E c-myc transgene. In addition, Msh2
Ϫ/Ϫ E c-myc and Msh2
G674A/G674A E c-myc tumors did not show evidence of compounded defects in the c-Myc-p53 apoptotic pathway compared with controls ( Fig. 4B ) (t test, P ϭ 0.011) showing that, by this analysis, these tumors had a similar phenotype to precursor-B cell lymphomas derived from wildtype E c-myc or MT Ϫ/Ϫ E c-myc mice (Fig. 2) . Although most E c-myc mice develop monoclonal B cell tumors (23) , it is possible that the enhanced lymphomagenesis observed in Msh2-deficient E c-myc mice is caused by an Fig. 3 .
Msh2 deficiency accelerates c-Myc-induced lymphomagenesis. Kaplan-Meier curves show overall survival of experimental mice. Msh2 Ϫ/Ϫ E c-myc and Msh2 G674A/G674A E c-myc mice rapidly succumb to c-Myc-induced lymphomagenesis (P Ͻ 0.0001). n denotes the number of mice in each group. Msh2G674A indicates Msh2 G674A/G674A mice. (14) is shown. IgD ϩ/Ϫ IgM ϩ ϩ B220 ϩ CD3 Ϫ cells were classified as mature/immature B cells, whereas IgD Ϫ IgM Ϫ B220 ϩ Ϫ CD3 Ϫ cells were further classified as pro B (BP-1 Ϫ ) or pre B (BP-1 ϩ ). The number of individual lymphomas analyzed in each group is indicated on top of the bars. Msh2 ϩ/ϩ E c-myc mice that were not part of the survival curve (Fig. 3) were also included to create a larger cohort. Msh2G674A indicates Msh2 G674A/G674A mice. (B) Western blot analysis for Mdm2, p53, and Arf protein from individual tumors derived from Msh2 ϩ/Ϫ , Msh2 Ϫ/Ϫ , and Msh2 G674A/G674A E c-myc mice. For Msh2 ϩ/Ϫ E c-myc mice, P indicates a pro/pre-B cell tumor, and M indicates a mature/immature B cell tumor. Lane C is a mouse tumor (Msh2 ϩ/Ϫ E c-myc tumor 8) that overexpresses Mdm2, p53, and Arf and is used as a positive control in this blot.
increased transformation rate of B cell clones on a per mouse basis (i.e., a polyclonal disease). To assess the clonality of tumors, we amplified DJ H rearrangements from tumor samples (Fig.  S5A) , as described (24) . Sequencing of DJ H rearrangements in Msh2 ϩ/Ϫ E c-myc and Msh2
Ϫ/Ϫ E c-myc tumors (Fig. S5B ) confirmed that all tumors were either monoclonal or oligoclonal in nature (Table S2) . Interestingly, Msh2 Ϫ/Ϫ E c-myc Tg tumors showed a predilection for the smallest recombination product, namely DJ H 4 (Fig. S5B) . One explanation for this observation is that repeated DJ recombination events occur until the final J H 4 segment is selected, akin to the sequential rearrangements observed during receptor revision (25) . In support of this notion, Ͼ50% of Msh2-deficient tumors were found to express RAG-1 transcripts (Fig. S5C) . This finding further agrees with the flow cytometric analysis that these tumors arise largely from a pro-B cell origin. Taken together, these data show that spontaneous lymphomas arising in Msh2 Ϫ/Ϫ E c-myc mice are not polyclonal, but rather monoclonal or oligoclonal in nature. Collectively, these data show that Msh2 plays an important role in suppressing pro-B cell tumors in E c-myc mice and further support the notion that early B cell progenitors are selectively prone to transformation.
Discussion
Overexpression of c-Myc is particularly prevalent in various types of B cell lymphomas, principally those that harbor chromosomal translocations between the c-Myc and antibody genes (26) . Some secondary mutations that complement c-Myc in cell transformation have been identified (see Introduction); however, the cellular processes responsible for these lesions are not known. It is clear that some of these lesions occur during early B cell ontogeny, because a significant proportion of E c-myc mice develop precursor stage B cell lymphomas (5, 6) . In this article, we show that genetic deficiencies leading to arrested B cell development and accumulation of early B cell precursors significantly enhance lymphoma development in E c-myc mice. One explanation for this finding is that arrested development at any stage of B cell ontogeny may predispose cells to transformation. However, lymphomagenesis is not accelerated in AID Ϫ/Ϫ E c-myc mice, yet deficiency in activation-induced cytidine deaminase (AID) has been shown to lead to the accumulation of B cells with a germinal center phenotype (27) . Thus, we favor the hypothesis that genetic deficiencies leading to the accumulation of B cell progenitors increases the pool of cells subject to transformation. In turn, this suggests either that the environment in which B cells develop is inherently mutagenic or that processes normally occurring within B cell progenitors predispose these cells to the accumulation of oncogenic mutations (see below).
It is unclear which stage of early B cell ontogeny is susceptible to transformation. In the absence of RAG-1, B cells are arrested at the pro-B cell stage (16) , because of an inability to productively rearrange their antigen receptor genes, whereas in MT Ϫ/Ϫ mice, B cells are arrested at the pre-B cell stage, because of an inability to express a functional membrane-bound Ig heavy chain (17) . An earlier report (28) showed that PLC␥2 Ϫ/Ϫ E c-myc mice exhibited accelerated lymphomagenesis; because of impaired signaling via the B cell receptor, deficiency in phospholipase C␥2 leads to a preferential increase in B220 ϩ sIg Ϫ cells and a decrease in the mature B220 high sIg ϩ population (29) . However, E c-myc/Ig double-Tg mice, which overexpress a prerearranged IgM BCR, do not exhibit accelerated lymphomagenesis (14) . These findings indicate that any B cell precursor stage before the acquisition of functional surface IgM expression is susceptible to transformation. By analogy, this situation also applies to T cell development, wherein thymomas have been observed to arise at high rates in various DNA repair-deficient backgrounds (e.g., ref. 12), or as a result of exposure to DNA mutagens (30) . It is unknown, however, whether the mechanism of transformation is similar between thymocytes and pro/pre-B cells. Considering the stochastic nature of spontaneous lymphomagenesis in mice that overexpress c-Myc, we hypothesized that the MMR pathway, given its prominent role in repairing mutations induced by DNA replication, oxidative radicals, and chemical agents (31, 32) , might function to actively suppress the acquisition of secondary mutations that coordinate with c-Myc to transform B cells. Indeed, Msh2 Ϫ/Ϫ E c-myc mice display a dramatically accelerated rate of developing pro-B cell lymphomas, thereby revealing that Msh2 normally suppresses c-Myc-induced transformation of B cell progenitors. Msh2 possesses the capacity to suppress c-Myc-induced lymphomas in different ways, each of which is not necessarily mutually exclusive in terms of mechanism. Although Msh2 has been shown to exert tumor-suppressor activity by functioning to prevent gross chromosomal aberrations (22, 31), we did not observe an increase in these events in Msh2 Ϫ/Ϫ E c-myc lymphomas, relative to controls (Table S1 ). Alternatively, Msh2 may also suppress tumor formation by inducing apoptosis in preneoplastic precursors in response to endogenous or exogenous DNA damage (33) . In this regard, the Msh2-dependent apoptotic response to endogenous insults such as oncogene overexpression has not been studied extensively, because most efforts have focused on exogenous DNAdamaging agents (20, 34) . Msh2-dependent apoptosis is mediated by the activation of p53 and/or the p53 homologs p63 and p73 (35) (36) (37) . A variety of intracellular and extracellular stressors, including DNA damage, hypoxia, and deregulated oncogene expression, have been shown to activate the p53 tumor suppressor via different pathways (38) . However, our work argues against an Msh2-dependent apoptotic response in suppressing lymphoma development in the E c-myc model, because lymphoma development in E c-myc mice homozygous for Msh2 G674A/G674A (a mutation that disrupts mismatch repair but does not affect apoptosis induction) was essentially indistinguishable from that arising in Msh2 Ϫ/Ϫ E c-myc mice (Fig. 3) . Because both Msh2 Ϫ/Ϫ and Msh2 G674A/G674A mice are MMR-deficient, it is therefore likely that the accumulation of somatic mutations in B cell progenitors is the causal mechanism behind the accelerated lymphomagenesis observed in the mutant E c-myc mice (21, 39) . Taken together, our data clearly indicate that the mismatch repair function of Msh2 is critical in preventing accelerated c-Myc-induced lymphomagenesis arising from early B cell precursors.
As mentioned above, our results suggest either that cellular processes active in precursor B cells are intrinsically mutagenic or B cell development occurs in an environment supportive of mutagenic outgrowth or both. Although it is likely that the RAG proteins do not provide the secondary lesions in conjunction with c-Myc to transform cells in this model (14, 40, 41) , other mutagenic processes may be responsible, such as unrepaired errors generated during DNA replication, given the rapid proliferation rate of precursor B cells. Alternatively, because certain distinct B cell precursor stages (i.e., pro-B cells and pre-B cells) are equally susceptible to transformation, and complete B cell development leading to functional IgM expression occurs in the bone marrow, it is also possible that the bone marrow environment provides an oncogenic milieu, for example, because of reactive oxygen species (ROS) combined with cytokine-driven proliferation, leading to widespread mutagenesis thereby facilitating lymphoma development. Even though c-Myc is overexpressed in fetal liver B cells during mid-to-late fetal development, the apparent absence of lymphomas in newborn wild-type or even Msh2 Ϫ/Ϫ E c-myc litters supports the notion that the bone marrow microenvironment may be more conducive to cellular transformation than the fetal liver microenvironment. It is also possible that the increased mutation rate of pro-B cells is the result of c-Myc overexpression itself, because c-Myc seems to lead to the accumulation of highly damaging ROS (42) , and ROS-exerted oxidative damage leads to point and frameshift mutations (43) . Because Msh2 is also shown to repair DNA damaged by ROS (44), our finding that Msh2 suppresses the acquisition of secondary mutations in precursor B cells in E c-myc mice is consistent with this possibility. This model also suggests that mutations complementing c-Myc to induce B cell transformation likely occur before genetic lesions involving c-Myc, such as chromosomal translocations. In our system, Msh2
Ϫ/Ϫ E c-myc hematopoietic cells may accumulate mutations long before cells commit to the B cell lineage. And once a clone harboring these secondary lesions fully commits to the B lineage, the E c-myc transgene is subsequently expressed, resulting in cellular immortalization at the pro-B cell stage (Fig. S6A) . In humans, numerous lymphomas harbor AID-induced c-Myc translocations, such as Burkitt's lymphoma (45) , represent immortalized centroblasts, suggesting that a B cell clone acquiring an AID-induced c-Myc/Igh translocation already harbored secondary mutations sufficient to promote immortalization (Fig.  S6B ).
Methods
Mice. TCR␣ Ϫ/Ϫ mice (46), TCR␦ Ϫ/Ϫ (47) and MT Ϫ/Ϫ mice (17) were interbred with E c-myc mouse (5, 6), which was purchased from Jackson Laboratories (stock number 002728). Msh2 ϩ/Ϫ mice (12) were kindly provided by Tak W. Mak (Ontario Cancer Institute, Toronto) and were bred to eventually generate Msh2 ϩ/ϩ , Msh2 ϩ/Ϫ , and Msh2 Ϫ/Ϫ E c-myc Tg littermates. The Msh2 G674A/G674A mouse, which has been described (21), was used to generate Msh2 G674A/G674A E c-myc mice. All mice were in the C57BL/6 genetic background and were bred and maintained under a specific pathogen-free environment. Mice were monitored daily for signs of morbidity and lymphoma development. Terminally ill mice were killed, and tumors from various sites were harvested to obtain single cell suspensions and subjected to flow cytometric analysis. Some tumor tissues were snap-frozen in liquid nitrogen for future use. The day at which a mouse was either killed or found dead because of lymphoma was used for Kaplan-Meier survival analysis.
Most of E c-myc mice died of apparent lymphoma. However, some TCR␣ Ϫ/Ϫ mice developed inflammatory bowel disease and rectal prolapse at Ϸ200 days. Therefore, subsequent analysis was also done by censoring all nonlymphoma-related deaths or limiting analysis to the first 180 days of the experiment. In either case, the survival difference between TCR␣ ϩ/Ϫ E c-myc mice and TCR␣ Ϫ/Ϫ E c-myc mice remained insignificant.
Flow Cytometry. Live lymphocytes were isolated from the single cell suspension of lymphomas and characterized by flow cytometry as described (14) , with some modifications. See Fig. S3 for details.
PCR and RT-PCR. Diversity/Joining (DJ) recombination products joints were amplified as described (24) . See Fig. S5 for details. Total RNA was isolated from tumor samples with TRIzol (Invitrogen) per the manufacturer's instructions. RNA was treated with DNase I (Fermentas) and reverse-transcribed using superScript III RT (Invitrogen). Gene expression was examined by using appropriate RAG1-and GAPDH-specific primers.
Immunoblotting. Protein extracts were prepared from tumor samples as described (8) . Proteins (Ϸ100 g per lane) were electrophoretically separated in 12% SDS/PAGE and transferred to nitrocellulose membranes (Pall). Membranes were blocked in 5% milk and blotted with antibodies specific for the mouse Mdm2 (C-18; Santa Cruz), Msh2 (Zymed), Arf (ab 80; Abcam) and internal control actin (Abcam), followed by HRP-conjugated anti-rabbit IgG antibodies and chemiluminescence detection. For p53 detection, membrane was blotted with sheep polyclonal Ab against mouse p53 (Ab-7; Calbiochem), followed by biotinylated rabbit anti-sheep secondary and streptavidin-HRP before chemiluminescence detection.
Statistics. Data were analyzed by using GraphPad Prism version 5.0. 
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